February 13, 2018

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor

im HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY.
Int J Cancer. 2018 Feb 13
February 8, 2018

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

Clara Montagut, MD, Guillem Argilés, MD, Fortunato Ciardiello, MD, Thomas T. Poulsen, PhD, Rodrigo Dienstmann, MD, Michael Kragh, PhD, Scott Kopetz, MD, Trine Lindsted, PhD, Cliff Ding, PhD, Joana Vidal, MD, Jenifer Clausell-Tormos, PhD, Giulia Siravegna, PhD, Francisco J. Sánchez-Martín, PhD, Klaus Koefoed, PhD, Mikkel W. Pedersen, PhD, Michael M. Grandal, PhD, Mikhail Dvorkin, MD, Lucjan Wyrwicz, MD, Ana Rovira, PhD, Antonio Cubillo, MD, Ramon Salazar, MD, Françoise Desseigne, MD, Cristina Nadal, MD, Joan Albanell, MD, Vittorina Zagonel, MD, Salvatore Siena, MD, Guglielmo Fumi, MD, Giuseppe Rospo, PhD, Paul Nadler, MD, Ivan D. Horak, MD, Alberto Bardelli, PhD, Josep Tabernero, MD
JAMA Oncol. Published online February 8, 2018. doi:10.1001/jamaoncol.2017.5245
December, 2017

Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.

Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Woude GFV, Jacobsen HJ, Horak ID, Kragh M, Lantto J, Bouquin T, Park M, Pedersen MW
Mol Cancer Ther. 2017 Dec;16(12):2780-2791
November 1, 2017

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz LJ. Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.
J Natl Cancer Inst. 2017 Nov 1;109(11)
July 5, 2017

Sym015: A highly efficacious antibody mixture against MET amplified tumors

Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M.
Clin Cancer Res. 2017 Jul 5. pii: clincanres.0782.2017. doi: 10.1158/1078-0432.CCR-17-0782. [Epub ahead of print]
PMID: 28679766 [PubMed - as supplied by publisher]
September, 2016

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL.
Mol Cancer Ther. 2016 Sep;15(9):2175-86
July, 2016

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.
Clin Cancer Res. 2016 Jul 1;22(13):3260-7
May, 2016

Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors

Takashi Kojima, Kentaro Yamazaki, Ken Kato, Kei Muro, Hiroki Hara, Keisho Chin, Thomas Goddemeier, Stefan Kuffel, Morihiro Watanabe, Toshihiko Doi, Kato K et al.
Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 2522-2522.
Read more about our mAb mixtures